The comparison of two different protocols ultra-long versus medroxyprogesterone acetate in women with ovarian endometriosis: a prospective randomized controlled trial

Table 1 Characteristics of women in two groups

Characteristics	MPA + HMG Group (n = 150)	Ultra-long Group (n = 150)	P
Number of cycles	150	150
Age, years	32.80 ± 3.43	32.46 ± 3.48	0.391
BMI (kg/m²)	21.61 ± 2.15	21.31 ± 2.68	0.231
Duration of infertility, y	3.15 ± 2.33	3.27 ± 2.57	0.672
Number of ET failures	0.32 ± 0.79	0.35 ± 1.09	0.761
Primary infertility, %	66 (99/150)	70.67 (106/150)	0.385
Antral follicle count, n	10.35 ± 3.92	10.57 ± 4.66	0.675
AMH (ng/ml)	3.26 ± 1.43	3.05 ± 1.16	0.562
Cyst surgery, %	68 (102/150)	64 (96/150)	0.465
Day 3 measures
FSH, IU/L	6.11 ± 1.46	5.74 ± 1.93	0.089
LH, IU/L	3.41 ± 1.39	3.28 ± 1.54	0.061
E2, pg/mL	40.10 ± 16.65	38.90 ± 17.29	0.588
P, ng/mL	0.29 ± 0.12	0.29 ± 0.14	0.595

P < 0.05: MPA + HMG group vs. Ultra-long group
BMI, body mass index; FSH, follicle stimulating hormone; LH, luteinizing hormone; E₂, estrogen; P, progesterone; AMH, anti-mullerian hormone

ISSN: 1742-4755